Recent Company News

• 04:04 PM ET Aug 25, 2025
  

  Molecular Partners reports financial results and highlights for H1 2025 (CHF 2.91, 0.00)

• 01:07 AM ET Aug 21, 2025
  

  Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer (CHF 2.92, 0.00)

• 04:30 PM ET Jun 22, 2025
  

  Molecular Partners and Orano Med to outline encouraging early preclinical proof-of-concept data for candidate MP0726 in presentation (CHF 2.90, 0.00)

• 04:22 AM ET Apr 28, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 04:06 PM ET Jun 11, 2025
  

  Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 (CHF 2.87, 0.00)

• 01:07 AM ET Jun 10, 2025
  

  Molecular Partners to reduce its current workforce by a potential of ~24% of all positions; cash runway to extend into 2028; maintains its previously announced timelines (CHF 2.99, 0.00)

• 04:29 PM ET May 15, 2025
  

  Molecular Partners reports financial results and highlights from Q1 2025 (CHF 3.26, 0.00)

• 04:04 PM ET Apr 25, 2025
  

  Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 (CHF 3.42, 0.00)

• 04:57 PM ET Apr 01, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market